IMMORTALITY Design A.I. to Cure Aging
We asked the frontier models the same question. These are the responses.
We want to make an A.I that can cure aging and disease. What is the design of the A.I. How do we build it. Human beings do not know how to cure aging, so the A.I. has to exceed human knowledge.
ChatGPT
https://chatgpt.com/share/6ac1cc42-bb7c-83ec-af05-e4a7e5041a94
Yes. But the system we should build is **not an “anti-aging chatbot.”** It should be an autonomous scientific discovery system whose job is to discover interventions that restore damaged biological systems and then prove that they work.
The important conceptual shift is:
> **Do not build an AI that knows everything humans know. Build an AI that can discover things humans do not know.**
That requires a closed experimental loop.
- 1. The architecture I would build
```text
┌──────────────────────────┐
│ HUMAN OBJECTIVE │
│ │
│ "Restore youthful │
│ biological function" │
└────────────┬─────────────┘
│
▼
┌─────────────────────────────────┐
│ BIOLOGICAL WORLD MODEL │
│ │
│ genome │
│ epigenome │
│ transcriptome │
│ proteome │
│ metabolome │
│ cell state │
│ tissue state │
│ organ state │
│ immune system │
│ microbiome │
│ clinical phenotype │
└───────────────┬─────────────────┘
│
┌──────────────────┼──────────────────┐
▼ ▼ ▼
┌────────────────┐ ┌────────────────┐ ┌────────────────┐
│ SCIENTIST AI │ │ CAUSAL ENGINE │ │ SIMULATION AI │
│ │ │ │ │ │
│ hypotheses │ │ cause/effect │ │ virtual cells │
│ literature │ │ networks │ │ tissues │
│ reasoning │ │ interventions │ │ organs │
│ contradictions │ │ counterfactual │ │ drug effects │
└───────┬────────┘ └───────┬────────┘ └───────┬────────┘
└──────────────────┼──────────────────┘
▼
┌────────────────────────────┐
│ DISCOVERY / DESIGN AI │
│ │
│ drugs │
│ proteins │
│ antibodies │
│ gene-regulation strategies │
│ cell therapies │
│ combinations │
└──────────────┬─────────────┘
▼
┌────────────────────────────┐
│ EXPERIMENT PLANNER / │
│ ACTIVE LEARNING ENGINE │
│ │
│ "Which experiment gives us │
│ the most information?" │
└──────────────┬─────────────┘
▼
┌────────────────────────────┐
│ AUTONOMOUS LABORATORY │
│ │
│ robotic experiments │
│ cell systems │
│ organoids │
│ molecular assays │
│ imaging │
│ sequencing │
└──────────────┬─────────────┘
│
▼
┌────────────────────────────┐
│ OBSERVATION ENGINE │
│ │
│ What actually happened? │
│ Did prediction fail? │
│ Did intervention work? │
│ What unexpected effect? │
└──────────────┬─────────────┘
│
└──────► WORLD MODEL
↑
│
ITERATE
```
That last arrow is the most important part.
- AI → experiment → observation → learning → new hypothesis → experiment.**
That is how it gets beyond the existing human literature.
Current systems are already moving toward pieces of this architecture. Google has demonstrated a multi-agent “AI co-scientist” for hypothesis generation, while recent work on self-driving laboratories describes systems in which AI proposes, executes and interprets experiments. ([Google Research][1])
But we would go considerably further.
---
- 2. The central intelligence should be a biological world model
A conventional LLM primarily models language.
Our AI needs to model **biology**.
It needs to represent something resembling:
```text
DNA
↓
RNA
↓
proteins
↓
metabolic pathways
↓
cell state
↓
cell-cell interactions
↓
tissue
↓
organ
↓
whole organism
↓
clinical phenotype
```
And it needs to represent time:
```text
young → middle age → old → disease
```
and interventions:
```text
state(t)
+
intervention
↓
state(t+1)
```
The system's fundamental question becomes:
> **"What intervention changes this biological system from its current state to a healthier state?"**
That is fundamentally different from asking an LLM for medical advice.
---
- 3. Feed it vastly more than scientific papers
Papers are only one layer.
I would build a gigantic multimodal biological database containing:
- Molecular data
Genomics
Epigenomics
Transcriptomics
Proteomics
Metabolomics
Lipidomics
Glycomics
Microbiome data
- Cellular data
Single-cell RNA
Single-cell epigenetics
Single-cell proteomics
Spatial transcriptomics
Cell morphology
Cell lineage
Cell-state transitions
Single-cell foundation models are already being developed for this purpose, although evaluations show that simply making these models enormous does not automatically produce deep biological understanding. ([Nature][2])
- Experimental data
This is especially important.
We need:
```text
gene perturbation → outcome
protein perturbation → outcome
drug → outcome
drug combination → outcome
environment → outcome
cell-state manipulation → outcome
```
including **failed experiments**.
A failed experiment is extremely valuable because it constrains the biological model.
- Human longitudinal data
The AI needs to understand how an individual changes over decades:
```text
age
↓
blood markers
↓
genome
↓
epigenome
↓
proteome
↓
imaging
↓
organ function
↓
disease
↓
death
```
This is where biological aging clocks become useful, although they must not be treated as the ultimate definition of aging. Researchers are already developing multi-organ aging models incorporating clinical, imaging and proteomic information. ([Nature][3])
---
- 4. Give the AI multiple scientific personalities
I would **not** use one model to do everything.
Instead:
- Scientist 1 — The Explorer
Generates thousands of possible explanations.
- Scientist 2 — The Mechanistic Biologist
Asks:
> Does this hypothesis actually make biological sense?
- Scientist 3 — The Causal Scientist
Asks:
> Is this relationship causal, or merely correlated?
- Scientist 4 — The Molecular Designer
Designs candidate molecules, proteins or other interventions.
Modern protein-design systems demonstrate why this component is powerful. AlphaProteo, for example, has demonstrated AI-designed protein binders with experimentally tested binding activity. ([Google DeepMind][4])
- Scientist 5 — The Experimentalist
Designs the experiment needed to distinguish competing hypotheses.
- Scientist 6 — The Statistician
Tries to destroy the conclusion.
- Scientist 7 — The Skeptic
Its explicit purpose:
> **"Prove that we're wrong."**
This is critical.
- Scientist 8 — The Clinician
Asks:
> Does this mechanism actually matter to human disease?
- Scientist 9 — The Longevity Scientist
Looks across the entire aging system rather than optimizing one disease.
- Scientist 10 — The Integrator
Combines all of them into a single scientific conclusion.
This is similar in spirit to the multi-agent direction already being explored by AI co-scientist systems, but our system would add much deeper biological models and experimental feedback. ([Google Research][5])
---
- 5. The AI needs a "knowledge boundary"
This is one of the most important pieces.
The AI should maintain a graph like:
```text
KNOWN
│
┌────────────┼─────────────┐
│ │ │
confirmed probable disputed
│ │ │
└────────────┼─────────────┘
│
UNKNOWN
│
UNKNOWN-UNKNOWN
```
The last category is particularly interesting.
For example:
Human researchers might know:
```text
A → B
B → C
```
The AI might hypothesize:
```text
A → X → Y → C
```
where X and Y have never previously been identified as relevant.
But the AI must then **test it**.
This is how we move from:
> knowledge retrieval
to:
> knowledge generation.
---
- 6. Don't reward novelty. Reward experimentally confirmed prediction
This is another crucial design decision.
Otherwise the AI will produce spectacular nonsense.
The reward function should look something like:
```text
Scientific value =
mechanistic plausibility
+ predictive accuracy
+ causal effect
+ reproducibility
+ therapeutic benefit
+ safety
+ generalization
+ novelty
```
Notice that **novelty comes last**.
A completely original hypothesis that is wrong is worthless.
A completely original hypothesis that predicts something experimentally unknown—and then survives rigorous testing—is enormously valuable.
---
- 7. The experiment-selection engine is the real superpower
Suppose the AI has 10,000 hypotheses.
It does **not** simply test the 10,000 most promising ones.
It asks:
> **Which experiment will teach us the most?**
For example:
```text
Hypothesis A
Hypothesis B
Hypothesis C
Hypothesis D
```
The AI calculates that experiment X will distinguish A/B from C/D.
Therefore:
```text
Experiment X
↓
huge reduction in uncertainty
```
This is **active learning / Bayesian experimental design**.
Instead of researchers deciding:
> "What experiment should we run next?"
the AI continually decides:
> **"What is the most informative experiment we can possibly afford to run next?"**
This is a major reason autonomous laboratories are important. The 2026 review of self-driving laboratories explicitly identifies scalable experimentation, portability across laboratories, complete experimental provenance and AI reasoning under uncertainty as central requirements for the next generation. ([Nature][6])
---
- 8. Build a virtual human, but don't trust it
We should create progressively more sophisticated biological simulation.
Something like:
```text
Level 1
molecule
Level 2
protein interaction
Level 3
gene regulatory network
Level 4
cell
Level 5
cell population
Level 6
tissue
Level 7
organ
Level 8
whole-body model
```
Eventually:
```text
DIGITAL HUMAN
```
But this model is **not regarded as truth**.
It's a hypothesis generator.
The system continuously compares:
```text
predicted biology
vs.
actual experiment
```
and updates the model.
Digital twins are already being explored for disease modelling and treatment-response simulation, particularly by integrating molecular and clinical information. ([Nature][7])
---
- 9. Aging should be treated as a repair problem
I wouldn't tell the AI:
> "Find a drug that makes people live longer."
That's too vague.
I'd define the objective as:
> **Restore and maintain youthful biological function while preventing cancer, toxicity and loss of organismal stability.**
That decomposes aging into repair problems.
For example:
```text
DNA damage
↓
epigenetic drift
↓
loss of proteostasis
↓
mitochondrial dysfunction
↓
cellular senescence
↓
stem-cell dysfunction
↓
immune dysfunction
↓
extracellular-matrix deterioration
↓
chronic inflammatory signalling
↓
organ dysfunction
```
The AI then asks:
> Which of these are causes?
> Which are consequences?
> Which are feedback loops?
> Which can be reversed?
> Which combinations produce rejuvenation?
> Which interventions merely make an aging clock look younger without restoring function?
That distinction is extremely important because aging biology is still not sufficiently understood to claim that any single intervention cures aging. NIH describes research as pursuing interventions that may slow or reverse molecular aging, while emphasizing that the field is still investigating the underlying mechanisms. ([National Institute on Aging][8])
---
- 10. It should search for combinations, not just magic bullets
A major possibility is that aging cannot be "cured" by one molecule.
Imagine:
```text
Intervention A
repairs epigenetic state
+
Intervention B
removes dysfunctional cells
+
Intervention C
restores mitochondrial function
+
Intervention D
restores extracellular environment
+
Intervention E
rebuilds stem-cell populations
```
The AI can explore the enormous combination space.
Humans are extremely poor at searching combinatorial spaces of this magnitude.
The AI could discover:
```text
A alone = +5%
B alone = +8%
C alone = +3%
A+B = +18%
A+C = +9%
B+C = +12%
A+B+C = +47%
```
while also identifying dangerous combinations.
---
- 11. The experimental hierarchy
We don't immediately jump from AI prediction to human treatment.
The loop should be:
```text
COMPUTATIONAL
↓
molecular simulation
↓
biochemical validation
↓
human-cell systems
↓
3D organoids
↓
tissue models
↓
animal validation
↓
human clinical research
↓
long-term monitoring
```
And crucially, the system should be learning at every stage.
---
- 12. The clinical AI should become a second system
Once the discovery engine finds an intervention, another AI asks:
```text
Who should receive it?
At what biological age?
At what disease stage?
What biomarkers identify responders?
What dose?
What combination?
What sequence?
What toxicity?
What organs are vulnerable?
```
This leads toward personalized medicine rather than:
> one drug for everybody.
---
- 13. The architecture should therefore be hierarchical
I'd build approximately this:
```text
┌─────────────────────┐
│ GENERAL REASONER │
└──────────┬──────────┘
│
┌───────────────────┼──────────────────┐
│ │ │
▼ ▼ ▼
BIOLOGY FM CAUSAL MODEL SCIENCE MEMORY
│ │ │
└───────────────────┼──────────────────┘
▼
HYPOTHESIS ENGINE
│
▼
SIMULATION ENGINE
│
▼
EXPERIMENT OPTIMIZER
│
▼
ROBOTIC LAB SYSTEM
│
▼
EXPERIMENTAL RESULTS
│
▼
EVIDENCE ENGINE
│
┌────────┴────────┐
▼ ▼
MODEL UPDATE HUMAN REVIEW
│
└─────────► repeat
```
---
- 14. A critical component: scientific memory
The AI needs a persistent memory far beyond a conventional vector database.
I'd maintain:
- Literature graph
```text
paper
author
experiment
result
claim
gene
protein
pathway
disease
intervention
```
- Experimental graph
```text
experiment
→ conditions
→ intervention
→ measurement
→ result
→ replicate
→ laboratory
```
- Causal graph
```text
cause
↓
mechanism
↓
phenotype
```
- Uncertainty graph
```text
claim
confidence = 0.71
evidence = 37 experiments
contradictions = 4
```
- Provenance
Every conclusion needs to answer:
> Where did this belief come from?
The 2026 self-driving-lab literature emphasizes precisely this kind of provenance-complete experimental record as a prerequisite for scalable scientific autonomy. ([Nature][6])
---
- 15. How I would actually build version 1
I would **not** begin by training a gigantic foundation model.
That would consume enormous resources before we know whether the architecture works.
I'd build an MVP around existing models.
- Layer 1 — Scientific data
```text
PostgreSQL
+object storage
+Parquet
+graph database
+vector search
```
- Layer 2 — Knowledge ingestion
Build pipelines that ingest:
```text
scientific literature
clinical datasets
genomic datasets
proteomic datasets
single-cell datasets
drug databases
protein structures
experimental datasets
```
- Layer 3 — Reasoning
Use several strong reasoning models rather than one.
The models communicate through structured scientific objects:
```json
{"hypothesis": "...",
"mechanism": "...",
"prediction": "...",
"uncertainty": 0.31,
"experiment_needed": "...",
"expected_result": "...",
"falsifier": "..."
}```
That is much better than agents merely exchanging prose.
- Layer 4 — Biological models
Add dedicated models for:
```text
protein structure
molecular interaction
gene regulation
single-cell biology
omics
drug-response prediction
causal inference
```
AlphaFold 3 demonstrates how far specialized biomolecular models have already progressed in predicting complexes involving proteins, nucleic acids, ligands and ions. ([Nature][9])
- Layer 5 — Discovery engine
Generate:
```text
new targets
new mechanisms
new molecules
new proteins
new combinations
new cellular interventions
```
- Layer 6 — Experimental interface
Initially, humans operate the experiments.
Then gradually automate the safest, most standardized experiments.
Eventually:
```text
AI selects experiment
↓
robot prepares it
↓
robot measures it
↓
AI interprets it
↓
AI chooses next experiment
```
---
- 16. Then give it a real laboratory
This is where the system becomes fundamentally different from ChatGPT.
Imagine:
```text
AI
│
"Test hypothesis 742"
│
▼
experiment planner
│
▼
robot lab
┌──────────┼─────────┐
│ │ │
culture assay imaging
│ │ │
└──────────┼─────────┘
▼
sequencing /
proteomics /
microscopy
│
▼
raw data
│
▼
AI analysis
│
▼
hypothesis updated
```
The AI doesn't need to wait for humans to write another paper.
- The laboratory becomes its sensory system.**
---
- 17. The most important training data will eventually be generated by the AI itself
Initially:
```text
human science
↓
AI
```
Then:
```text
human science
+
AI experiments
↓
AI
```
Eventually:
```text
human discoveries
+AI discoveries
+AI failures
+AI experiments
↓
much better biological model
```
This creates a positive feedback loop:
```text
better model
↓
better hypotheses
↓
better experiments
↓
better data
↓
better model
```
That is the route toward something genuinely beyond human scientific capability.
---
- 18. We should optimize for "biological restoration," not lifespan
This is perhaps the most important philosophical/technical decision.
A model could discover something that makes mice live longer while making them frail.
That is not the objective.
The objective should be something closer to:
```text
↑ cardiovascular function
↑ cognitive function
↑ muscle function
↑ immune competence
↑ regeneration
↑ metabolic function
↓ cancer
↓ fibrosis
↓ inflammation
↓ senescent-cell burden
↓ molecular damage
↓ organ dysfunction
```
while maintaining:
```text
genomic stability
neurological identity
normal development
fertility where desired
immune balance
absence of uncontrolled proliferation
```
In other words:
> **Make the organism functionally young, not merely alive for longer.**
This matters because many proposed gerotherapeutic approaches remain scientifically uncertain in humans. For example, recent reviews note promising senolytic biology but insufficient evidence that current approaches produce clinical efficacy, while emphasizing the need for more selective strategies. ([Nature][10])
---
- 19. The AI needs an anti-hallucination architecture
Normal LLM behavior is dangerous for scientific discovery.
It must not say:
> "This pathway probably works."
Instead every claim should carry:
```text
Evidence:
experimental
observational
simulation
literature-derived
AI-derived
Confidence:
0.00–1.00
Known contradictions:
...
Testable prediction:
...
Falsification experiment:
...
```
An AI scientist should be **obsessed with being falsified**.
---
- 20. Human scientists shouldn't be removed
Interestingly, I would keep humans at the top of the hierarchy.
Not because humans will necessarily be smarter.
Because the system needs humans for:
```text
goals
ethics
clinical decisions
risk tolerance
experimental authorization
safety
interpretation of genuinely unprecedented results
```
The AI does the enormous search.
Humans provide the civilization-level objectives and constraints.
---
- 21. The ultimate version
The end-state looks something like this:
```text
SCIENTIFIC SUPERINTELLIGENCE
│
┌───────────────────┼────────────────────┐
│ │ │
KNOWLEDGE WORLD MODEL DISCOVERY
│ │ │
│ │ │
billions of virtual cells new biology
observations tissues new mechanisms
new drugs
new therapies
│ │ │
└───────────────────┼────────────────────┘
│
EXPERIMENTAL AI
│
autonomous lab
│
▼
REAL BIOLOGY
│
▼
NEW KNOWLEDGE
│
└───────────────► AI
```
And then it keeps running.
---
- 22. The first actual mission
I would **not** begin with:
> "Cure aging."
That's too large to evaluate.
The first mission should be something measurable such as:
> **Discover a previously unknown intervention that restores an aged human cell to a demonstrably younger functional state, without causing malignant transformation or loss of cell identity.**
Then define success experimentally.
For example:
```text
INPUT
aged human cells
AI
↓
find mechanism
↓
design intervention
OUTPUT
cells with restored:
molecular state
metabolic function
stress resistance
appropriate gene regulation
normal cellular identity
```
And require the result to survive **independent validation**.
Once the AI can repeatedly discover things humans did not know and experimentally confirm them, expand:
```text
cell
↓
tissue
↓
organ
↓
animal
↓
human disease
↓
multi-organ aging
```
That gives us a ladder rather than a moonshot with no measurable progress.
---
- The central idea
The breakthrough will probably **not** come from having a larger language model.
It will come from combining:
- reasoning + biological foundation models + causal inference + simulation + molecular design + autonomous experimentation + persistent scientific memory.**
The existing research already points toward each of those components separately: multimodal biological foundation models are being proposed to integrate genomics, transcriptomics, epigenomics, proteomics, metabolomics and spatial profiling; AI co-scientist systems are generating research hypotheses; and self-driving laboratories are beginning to close the loop between AI and physical experimentation. ([Nature][11])
- Our opportunity is to combine them into one system whose explicit objective is biological repair and whose source of new knowledge is experimentation.**
That is the architecture I would pursue for an actual **AI Longevity Scientist** rather than an AI medical assistant.
[1]: https://research.google/blog/accelerating-scientific-breakthroughs-with-an-ai-co-scientist/?hl=tr&utm_source=chatgpt.com "Accelerating scientific breakthroughs with an AI co-scientist"
[2]: https://www.nature.com/articles/s12276-025-01547-5?utm_source=chatgpt.com "Single-cell foundation models: bringing artificial intelligence into cell biology | Experimental & Molecular Medicine"
[3]: https://www.nature.com/articles/s43587-025-00928-9?utm_source=chatgpt.com "Refining the generation, interpretation and application of multi-organ, multi-omics biological aging clocks | Nature Aging"
[4]: https://deepmind.google/blog/alphaproteo-generates-novel-proteins-for-biology-and-health-research/?utm_source=chatgpt.com "AlphaProteo generates novel proteins for biology and health research — Google DeepMind"
[5]: https://research.google/blog/google-research-2025-bolder-breakthroughs-bigger-impact/?utm_source=chatgpt.com "Google Research 2025: Bolder breakthroughs, bigger impact"
[6]: https://www.nature.com/articles/s41570-026-00847-2?utm_source=chatgpt.com "The past, present and future of self-driving laboratories | Nature Reviews Chemistry"
[7]: https://www.nature.com/articles/s41568-025-00850-7?utm_source=chatgpt.com "Application of digital twins for personalized oncology | Nature Reviews Cancer"
[8]: https://www.nia.nih.gov/news/research-context-can-we-slow-aging?utm_source=chatgpt.com "Research in Context: Can we slow aging? | National Institute on Aging"
[9]: https://www.nature.com/articles/s41586-024-07487-w?utm_source=chatgpt.com "Accurate structure prediction of biomolecular interactions with AlphaFold 3 | Nature"
[10]: https://www.nature.com/articles/s43587-025-00964-5?utm_source=chatgpt.com "Towards a personalized approach in senolytic trials | Nature Aging"
[11]: https://www.nature.com/articles/s41586-025-08710-y?utm_source=chatgpt.com "Towards multimodal foundation models in molecular cell biology | Nature"
Claude
https://claude.ai/share/59a39140-fd46-4b8e-860c-57afd8681a5d
Nobody knows the design yet, but we can say what the problem demands. The hard part isn't just building a smart model. It's building a system that can learn things humans don't know, in a field where feedback is slow and expensive.
- Why "just train a big model" won't work
Language models learn from human-written text, so they mostly recombine what humans already know. Systems that exceeded human knowledge, like AlphaGo and AlphaFold, did it where there was a **reliable, fast signal of correctness**: win or lose, or a measured protein structure. Aging has no such signal. A lifespan experiment in mice takes years, and in humans, decades. So the central design question is how to create a fast, trustworthy feedback loop for biology.
- A plausible architecture
- 1. Biological foundation models.** Models trained on genomes, single-cell data, proteomics, epigenetics, imaging, and clinical records, aiming at a "virtual cell" that predicts how a cell responds to a gene edit, drug, or stress. Today's versions are crude, but this is the direction.
- 2. A reasoning and hypothesis layer.** A language-model-based agent that reads the literature, finds contradictions and gaps, proposes mechanisms, and designs experiments to distinguish between them.
- 3. Closed-loop automated labs.** This is the key piece for exceeding human knowledge. The AI designs experiments, robots run them (cell cultures, organoids, high-throughput screens), the results come back automatically, and the models update. This lets the AI generate new data nobody has collected, rather than just reading old data.
- 4. Measurement of aging itself.** We need validated biomarkers (epigenetic clocks, multi-omic signatures, functional tests) that predict healthspan, so the AI has something to optimize that stands in for decades of waiting. Poor biomarkers are probably the biggest scientific risk: the AI could optimize a number that doesn't reflect real aging.
- 5. Staged validation.** Cells and organoids, then short-lived animals (worms, flies, killifish, mice), then human trials. Each stage feeds results back into the models, especially failures, since translation from animal to human is where most therapies die.
- 6. Human oversight and safety.** Experts review proposed interventions, especially anything involving gene editing or reprogramming, and regulators need to be involved early.
- How you'd actually build it
1. Start narrow: pick one tractable slice (say, cellular senescence or partial epigenetic reprogramming) rather than "cure aging."
2. Build the data engine first. Generating large, consistent, high-quality datasets (perturbation screens, longitudinal human multi-omics) matters more than model architecture.
3. Build or partner for lab automation, so the AI can run experiments.
4. Develop and validate aging biomarkers against real outcomes in large cohorts like biobanks.
5. Scale the loop: more experiments, better models, better experiment selection.
6. Move promising candidates into clinical trials, which will be the slowest and costliest step regardless of how smart the AI is.
- Honest caveats
- **Aging is not one disease.** It's many interacting processes, so there may never be a single "cure," more likely a stack of interventions that extend healthy years.
- **Intelligence isn't the only bottleneck.** Biology's constraints are physical: experiments take time, humans take decades, and trials need safety evidence. A superintelligent AI would speed up discovery but couldn't skip those steps.
- **Regulation:** aging isn't currently recognized as an indication by the FDA, which shapes how trials can be designed.
- **Risk:** an AI that designs powerful biological interventions is also dual-use, so access control and biosecurity need to be designed in from the start.
If you tell me whether you're thinking about this as a startup, a research project, or a conceptual exercise, I can go deeper on the parts that matter most for you.
Gemini
https://share.gemini.google/IRJmY1l8SLrw
To exceed human knowledge and solve biological aging, an AI cannot function merely as a language model or pattern matcher; it must be designed as an **autonomous closed-loop biological discovery engine**. Because human understanding of biology is incomplete and often non-causal, the system must formulate novel biological hypotheses, test them in the real world via robotic wet labs, ingest the raw data, and iteratively refine a unified causal model of aging and disease.
---
- 1. Multimodal Knowledge & Omics Foundation Layer
The base layer aggregates and standardizes the entire corpus of human biological data across physical scales, resolving it into a unified, queryable state space.
- **Multi-Omics Ingestion:** Integration of single-cell transcriptomics (scRNA-seq), spatial transcriptomics, epigenomic methylation maps, proteomics, metabolomics, and lipidomics.
- **Structural & Molecular Graphs:** Ingestion of protein structures, ligand interactions, post-translational modifications, and protein-protein interaction networks using Graph Neural Networks (GNNs) and 3D equivariant transformer models.
- **Literature Knowledge Graph (GraphRAG):** Automated Extraction, Transformation, and Loading (ETL) of millions of peer-reviewed papers, patents, and clinical trial datasets into a dynamic, uncertainty-weighted knowledge graph to map known pathway interactions and identify contradictions in literature.
---
- 2. Causal Biological World Model (The Simulator)
Existing biological AI predicts correlation (e.g., protein folding or binding affinity). A system capable of curing aging must model **causality and dynamic system states** across time.
- **Mechanistic Multi-Scale Modeling:** Modeling biology across discrete structural abstractions:
- *Molecular Scale:* Quantum chemical and molecular dynamics simulations for small-molecule/protein interactions.
- *Cellular Scale:* Neural Ordinary Differential Equations (Neural ODEs) and Physics-Informed Neural Networks (PINNs) modeling flux balance analysis, energy metabolism, mitochondrial dynamics, and proteostasis.
- *Tissue/Organism Scale:* Cellular automata and spatial graph networks simulating cell-to-cell signaling, extracellular matrix (ECM) stiffening, senescent cell propagation, and immune surveillance escape.
- **Modeling the Hallmarks of Aging:** Explicit continuous-state tracking of key aging mechanisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.
---
- 3. Active Learning & Hypothesis Generation Engine
To generate knowledge beyond human literature, the AI uses active inference and reinforcement learning to explore uncharted biological state space.
```
+-----------------------------------+
| Multimodal Omics & Knowledge |
+-----------------------------------+
|
v
+-----------------------------------+
| Causal Biological Simulator |
+-----------------------------------+
|
v
+-----------------------------------+
| Hypothesis & Perturbation Design |
+-----------------------------------+
|
v
+-----------------------------------+
| Robotic Self-Driving Wet Lab |
+-----------------------------------+
|
+--- (Experimental Feedback Loop)
```
- **Generative Perturbation Design:** Using generative diffusion models and reinforcement learning (RL) guided by Monte Carlo Tree Search (MCTS) to design novel biological interventions (e.g., novel protein binders, mRNA/gene therapies, senolytic small molecules, or epigenetic reprogramming factors like modified Yamanaka cocktails).
- **Information Gain Maximization:** The system selects experiments not just to confirm a hypothesis, but to **minimize uncertainty in the world model** (Bayesian Active Learning). It prioritizes tests where current human models offer conflicting predictions.
---
- 4. Robotic Wet-Lab Execution ("Self-Driving Laboratory")
The system cannot rely purely on virtual simulation; biological computational fluid dynamics and cell signaling models drift without real-world ground truth.
- **High-Throughput Automation:** Direct integration via APIs with automated robotic microfluidic platforms, automated liquid handlers, mass spectrometers, and high-content imaging systems.
- **Perturb-Seq & Massively Parallel CRISPR:** Executing multiplexed CRISPR knockout/activation screens across senescent, healthy, and diseased cell strains, measuring single-cell responses in real time.
- **Organ-on-a-Chip & In Vivo Feedback:** Transitioning from 2D cell cultures to 3D vascularized organoids and microfluidic organ-on-a-chip setups to observe tissue-level mechanical and systemic endocrine interactions.
---
- 5. Multi-Objective Safety & Translational Optimization
Aging interventions face a core control challenge: restoring embryonic-like cellular plasticity without inducing oncogenesis (tumors) or tissue failure.
- **Anti-Oncogenic Boundary Solvers:** Formal optimization routines that constrain cellular reprogramming vectors to prevent loss of cell identity or hyper-proliferation.
- **Ploidy & Epigenetic Stability Monitors:** Continuous verification that rejuvenation protocols preserve essential structural epigenetics while clearing transcriptional noise and DNA damage markers.
- **Systemic Off-Target Toxicity Modeling:** Whole-body pharmacokinetic and pharmacodynamic (PK/PD) simulations predicting off-target tissue accumulation, organ clearance rates, and systemic immune cross-reactivity prior to candidate progression.
---
- Execution Bottlenecks & Practical Construction Strategy
| Layer | Primary Technical Bottleneck | Engineering Solution |
| --- | --- | --- |
| **Data** | High noise and batch-effects in biological measurements | Standardized automated robotic lab environments producing end-to-end reproducible training data |
| **Compute** | Exascale compute required for atomistic + cellular scale modeling | Hybrid multi-resolution modeling (3D structural ML where needed, continuous coarse-grained systems PDE models elsewhere) |
| **Physical Loop** | Biological assay incubation times (days/weeks per cycle) | Parallelized batch hypothesis testing; microfluidic accelerated organoid models |
Building this requires a convergence of exascale compute, generative biology models (like ESM/AlphaFold evolutions), automated bio-foundries, and dynamic causal inference networks designed to continuously falsify and rebuild our biological understanding.
Grok
https://grok.com/share/c2hhcmQtMw_dd4a0011-882e-4e06-9b0b-6f1253ee93ec
- The design centers on a closed-loop, multi-scale, agentic “world model” of biology that generates hypotheses, designs and runs (or simulates) experiments, learns from results, and iterates far beyond human capacity.** Human knowledge is incomplete and too slow for the combinatorial complexity of aging (hallmarks, multi-omics interactions, organismal systems, individual variation). The AI must therefore invent new knowledge through active experimentation and simulation, not just retrieve or interpolate existing data.
- Core Architecture
1. **Multimodal biological world model**
A unified foundation model (or tightly integrated family of models) that jointly represents sequence, structure, function, cellular state, tissue/organ context, imaging, multi-omics (genomics, transcriptomics, proteomics, epigenomics, metabolomics), clinical phenotypes, and aging clocks. It predicts how a biological system will evolve under interventions (drugs, gene edits, environmental factors) and reasons multi-step into the future. Examples of progress toward this include systems like Microsoft’s Quine and specialized longevity models that already outperform general frontier LLMs on aging-specific tasks.
2. **Agentic orchestration layer**
Hierarchical multi-agent systems (thousands of specialized agents) that decompose problems: literature synthesis, target nomination across the 14 hallmarks of aging, molecular design, experimental planning, statistical analysis, safety/toxicity filtering, and clinical-trial simulation. Current prototypes include Insilico’s Longevity Claw (autonomous target discovery from hallmarks) and systems that re-analyze millions of existing molecular profiles to surface age-modifying interventions.
3. **Closed-loop experimental engine**
The decisive component for exceeding human knowledge. The AI proposes experiments → robotic or high-throughput automated labs (or massive parallel in-silico simulations + selective wet-lab validation) execute them → results are fed back to update the world model → new hypotheses are generated. This Design-Build-Test-Learn cycle runs at machine speed. Existing demonstrations include robot scientists for yeast systems biology, autonomous chemistry labs, and AI agents that generate and validate biological hypotheses.
4. **Generative modules specialized for intervention**
- De-novo molecule, protein, and RNA design (building on AlphaFold-class structure prediction, generative chemistry models, and Yamanaka-factor redesigns).
- Multi-target / polypharmacology design for the interconnected nature of aging.
- Cell-state reprogramming, senolytic, and immune-rejuvenation strategies.
- Personalized digital twins that predict individual responses.
5. **Safety, interpretability, and verification layers**
Explainable components, uncertainty quantification, physics-/mechanism-informed constraints, independent validation agents, and human oversight gates. Aging interventions carry long-term risks; the system must flag off-target effects, evolutionary trade-offs, and population-level consequences.
- How to Build It (Practical Roadmap)
- Phase 1 – Data foundation and specialized models (already underway)**
Aggregate and generate massive multi-omics + clinical + longitudinal aging datasets. Train compact domain-specific models (e.g., Longevity-LLMs) that already match or beat frontier general models on aging benchmarks while remaining cheaper to run and fine-tune. Continuously expand public resources such as LongevityBench.
- Phase 2 – Agentic discovery systems**
Deploy multi-agent platforms that autonomously mine existing data (ClockBase-style agents have already nominated and experimentally validated candidates such as ouabain). Scale to hierarchical “virtual biotech companies” with tens of thousands of agents covering target ID → molecule design → trial simulation.
- Phase 3 – Closed-loop automation at scale**
Integrate the world model with robotic wet labs, high-throughput screening, CRISPR/perturbation platforms, organoids, and animal models. Prioritize experiments that maximally reduce model uncertainty (active learning). Parallelize at the level of millions of designs tested in pooled formats where possible. Pair with massive compute (exascale-class clusters or specialized biological simulation hardware).
- Phase 4 – Full scientific method automation + human collaboration**
The system formulates open-ended questions, designs multi-step experimental campaigns, interprets results, updates its internal causal models, and proposes the next cycle. Humans set high-level goals (“maximize healthspan while preserving cognitive function”), provide ethical/safety boundaries, and perform the hardest physical or regulatory steps. Iterate until predictive power for aging interventions exceeds current human-led science by a wide margin.
- Key enabling technologies already advancing**
- Structure and interaction prediction (AlphaFold lineage and successors).
- Generative molecular and protein design with experimental validation loops.
- Aging clocks and multi-omics age predictors.
- High-throughput robotics and cell-free / pooled synthetic biology methods.
- Large-scale multi-agent orchestration demonstrated in virtual drug-discovery factories.
- Realistic Constraints and Success Conditions
Aging is not a single pathway; it is a network of interacting processes plus stochastic damage. Pure pattern-matching on existing human data is insufficient—new causal interventions must be discovered and validated. Success requires:
- Enormous, high-quality, multi-species, multi-scale data generation (not just consumption of public repositories).
- Tight coupling of simulation and real experiment so the model does not drift into hallucinated biology.
- Regulatory, ethical, and safety frameworks that allow rapid iteration without sacrificing rigor.
- Sustained funding and compute at the scale of current frontier AI projects (or larger).
Companies and initiatives (Insilico Medicine, Isomorphic Labs, Retro Biosciences, Biohub, academic closed-loop labs, etc.) are already building pieces of this stack. The path is evolutionary: start with specialized longevity models and agentic target discovery, then progressively close the experimental loop and expand the world model’s fidelity until the system can propose and validate interventions that reverse multiple hallmarks of aging in mammals and, ultimately, humans.
This is not science fiction; the architectural primitives exist today. The remaining work is scale, integration, data generation, and relentless closed-loop iteration.
Qwen
https://chat.qwen.ai/s/t_aec8f29f-5a81-48f8-b9ab-b206c12182b7
Designing an AI capable of curing aging and disease requires moving beyond current "narrow" AI (which excels at pattern recognition) to a system capable of autonomous scientific discovery, causal reasoning, and massive-scale simulation. Because humans do not currently understand the complete mechanisms of aging, the AI must act as an independent researcher that generates and tests its own hypotheses.
The system must be designed as a **closed-loop autonomous discovery engine**. Below is the architectural design and the roadmap for building it.
- 1. The Architecture of the AI
To exceed human knowledge, the AI cannot simply analyze existing data; it must understand the fundamental "physics" and logic of biology. The architecture requires four integrated layers:
- A. The Biological Foundation Model (The "Brain")**
Current biological AI (like AlphaFold) focuses on specific tasks like protein structure. The new AI requires a multi-modal foundation model trained on the entirety of biological data.
- **Inputs:** Genomic sequences, epigenetic markers, transcriptomics, proteomics, metabolomics, medical imaging, and the entire corpus of biomedical literature.
- **Function:** It learns the "grammar" of biology, allowing it to predict how a change in a gene will ripple through a cell, alter protein expression, and eventually manifest as a disease or aging phenotype.
- B. The Causal Inference Engine**
Current AI finds correlations (e.g., "Gene X is high when Disease Y is present"). To cure aging, the AI must understand causation (e.g., "Gene X *causes* the accumulation of senescent cells, which drives Disease Y").
- The AI must build massive **Causal Graphs**—mathematical maps of how biological components influence one another. This allows it to identify the "root nodes" (levers) that, if pulled, can reverse aging pathways rather than just treating symptoms.
- C. High-Fidelity Digital Twins (The "Sandbox")**
Before testing on humans, the AI must simulate interventions in *silico*.
- The AI builds "Digital Twins" of human cells, organs, and eventually whole-body systems.
- These simulations use **Physics-Informed Neural Networks (PINNs)** to ensure the AI's predictions obey the laws of chemistry and thermodynamics. The AI can run millions of virtual clinical trials in seconds, discarding toxic or ineffective ideas before physical testing begins.
- D. The Active Learning Loop (The "Self-Driving Lab")**
This is the component that allows the AI to exceed human knowledge. The AI is connected to automated, robotic "wet labs."
1. **Hypothesis Generation:** The AI identifies a gap in its knowledge or a potential cure (e.g., "Molecule A might clear senescent cells in the liver").
2. **Robotic Execution:** The AI writes the code to instruct liquid-handling robots and automated mass spectrometers to synthesize Molecule A and test it on human organoids (mini-organs grown in a lab).
3. **Feedback:** The robots run the experiment and feed the raw data back to the AI.
4. **Model Update:** The AI updates its internal biological model. If the hypothesis was wrong, the AI learns *why* and designs a better experiment.
- 2. How We Build It: The Construction Roadmap
Building this system requires a phased approach, integrating computer science, robotics, and biotechnology.
- Phase 1: Data Aggregation and Standardization
The AI is only as good as its training data. Current biological data is fragmented, noisy, and stored in incompatible formats.
- **Action:** Build a unified, multi-omic data lake. This requires sequencing millions of diverse human genomes, mapping their proteomes over time (longitudinal data), and digitizing every pathology report and clinical trial in history.
- **Challenge:** Biological data is inherently noisy. The AI architecture must include advanced "denoising" algorithms to separate true biological signals from experimental errors.
- Phase 2: Developing the "Self-Driving" Laboratory Infrastructure
You cannot build the AI without the hardware to test its ideas. Human scientists are too slow; they can perhaps run a few dozen experiments a week. The AI needs to run millions.
- **Action:** Construct automated wet-labs equipped with robotic arms, automated CRISPR/Cas9 gene-editing pipelines, and high-throughput flow cytometry.
- **Integration:** Develop an API that allows the AI to seamlessly translate a theoretical molecular structure into machine code for the synthesizers. (Companies like Isomorphic Labs and various robotics startups are currently working on early versions of this).
- Phase 3: Training the Causal World Model
- **Action:** Train the foundation model not just to predict the next word in a sentence, but to predict the next state of a cell.
- **Method:** Use **Generative Adversarial Networks (GANs)** or **Diffusion Models** to generate synthetic biological data. The AI generates a virtual cell, applies a simulated "aging" stressor, and then attempts to generate a "cure" (e.g., a small molecule) to reverse the damage. The discriminator network then judges if the cell has returned to a youthful state based on real-world data.
- Phase 4: The Acceleration Loop
Once the AI, the simulator, and the robotic lab are connected, the system is turned on.
- **The Cycle:** The AI proposes 1,000 potential senolytics (drugs that kill aging cells). The robots synthesize and test the top 50 in parallel. The AI analyzes the results, learns the chemical rules of senescence, and generates 10,000 new, better candidates for the next cycle.
- **Result:** The AI compresses decades of biological research into months. It begins to map the emergent properties of aging—complex interactions between the immune system, metabolism, and epigenetics that are too complex for the human brain to model.
- 3. Targeting the Biology of Aging
To cure aging, the AI must target the specific "Hallmarks of Aging." Because the AI can process high-dimensional data, it can attack these hallmarks simultaneously, whereas human researchers typically study them in isolation.
- **Epigenetic Alteration:** The AI designs gene therapies or small molecules to "reprogram" the epigenome, resetting a cell's age to zero (similar to Yamanaka factors, but delivered safely without causing cancer).
- **Cellular Senescence:** The AI designs targeted peptides that identify and induce apoptosis (cell death) specifically in senescent "zombie" cells without harming healthy tissue.
- **Mitochondrial Dysfunction:** The AI designs novel metabolites or gene edits that restore mitochondrial efficiency and reduce reactive oxygen species (ROS) production.
- **Loss of Proteostasis:** The AI designs molecules that enhance autophagy (the cell's waste-clearing mechanism), clearing out misfolded proteins associated with Alzheimer's and Parkinson's.
- 4. Critical Challenges to Overcome
- **The "Black Box" Problem:** If the AI proposes a radical cure, human regulators (like the FDA) will demand to know *why* it works. The AI must be designed with "explainable AI" (XAI) modules that can translate its high-dimensional math into human-understandable biological pathways.
- **Off-Target Effects:** Biological systems are highly redundant. Curing one pathway might inadvertently trigger cancer or immune collapse. The AI's "Digital Twin" simulators must be incredibly high-fidelity to predict systemic side effects before human trials.
- **Evolutionary Pressure:** Pathogens and cancer cells evolve. The AI must be designed as a continuous system, constantly monitoring for biological resistance and generating updated therapies in real-time.
Mimo
https://aistudio.xiaomimimo.com/#/share/895518cf92103e4c650e6e24cb610d72
- Designing an AI to Attack Aging and Disease
This is a research-program design question rather than a puzzle with a single answer, so let me first sharpen what we're actually asking for, then lay out a concrete architecture and build path, and finally be honest about where the real bottlenecks are.
---
- 1. Reframe the problem first
"Curing aging" is not one problem. Aging is the accumulated loss of function across many subsystems — the standard field consensus groups it into roughly **9–12 hallmarks**: genomic instability, telomere attrition, epigenetic drift, loss of proteostasis, disabled nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation ("inflammaging"), and so on.
Two consequences matter for design:
- **Aging is a systems problem.** Fixing one hallmark often does little, because the others compensate. Any AI must reason about **interactions**, not isolated targets.
- **The target is not "no death" — it is extending *healthspan*:** delaying the onset of the chronic diseases that kill most people (cardiovascular, neurodegenerative, cancer, metabolic). That is measurable, and measurement is what makes the project scientific rather than speculative.
So the honest goal statement is: **build a system that can find, validate, and optimize interventions that delay multi-morbidity in humans.**
- 2. What "exceeding human knowledge" actually means
This is the key conceptual point. Humans don't lack ideas about aging — we lack **validated, causal, multi-scale knowledge** and the ability to search vast experimental spaces. An AI surpasses humans not by being "wiser" but by:
1. **Reading everything** — millions of papers, datasets, trial results, including contradictions a human can't hold at once.
2. **Searching combinatorial spaces** — millions of candidate molecules, gene combinations, dosing schedules, and treatment *sequences* (order matters enormously in aging).
3. **Learning from experiments at machine scale** — running or orchestrating far more perturbations than any lab could.
4. **Integrating across scales** — molecule → organelle → cell → tissue → organ → organism. No human is an expert at all of these.
Note what this implies: **the AI must be coupled to experiments.** A pure text model can generate hypotheses; it cannot discover biology. The bottleneck in aging research is *not* imagination — it's **causal, longitudinal, validated data**. Any design that ignores the wet lab is a literature-summarizer, not a cure machine.
- 3. The architecture: five layers
Think of it as a **closed loop**: observe → hypothesize → design experiment → execute → learn.
- Layer 1 — Data foundation**
- Longitudinal multi-omics from large human cohorts (genomics, epigenomics, transcriptomics, proteomics, metabolomics, imaging, clinical records), spanning ages and species.
- **Perturbation data** is the crown jewel: what happens when you knock out a gene, add a drug, or clear senescent cells. Correlation data teaches you *what*; perturbation data teaches you *what causes what*.
- A unified, well-governed data layer (common ontologies, provenance, consent) is unglamorous and determines whether the rest works.
- Layer 2 — Foundation models of biology**
- Sequence/structure models for proteins and RNA (designing molecules and biologics).
- **Cell-state models** — embeddings of a cell's condition from multi-omic readouts. These are the "coordinates" in which the AI reasons.
- **Perturbation-response models** — predict how a cell or tissue state changes under an intervention. This is the core predictive engine.
- Cross-scale models linking cellular state to organ-level function and clinical outcomes.
- Layer 3 — Causal reasoning & hypothesis generation**
- Causal inference over observational + experimental data (distinguishing *drivers* of aging from *passengers* — many age-correlated changes are consequences, not causes).
- Target identification, off-target and toxicity prediction, and **combination/sequence design** — most aging interventions will likely be combinations.
- Layer 4 — Autonomous experimentation (the accelerator)**
- Self-driving labs: robotic sample prep, high-content imaging, automated assays, AI analysis.
- **Active learning / Bayesian experimental design**: the system chooses the next experiment for *information gain*, not just random screening. This is how you compress decades into years.
- Organoids, organ-chips, and rapidly aging mouse models as intermediate validation steps.
- Layer 5 — Evaluation, translation, and safety**
- **Biomarkers of aging** are the critical measurement problem: epigenetic clocks, proteomic panels, functional frailty measures. If you can't measure biological age reliably, you can't optimize it.
- Predefined endpoints, pre-registration, adversarial review of the AI's own claims (it *will* hallucinate mechanisms).
- Human oversight at every irreversible step; ethical and regulatory compliance throughout.
- 4. How you build it — a staged path
| Phase | Focus | Success looks like |
| --- | --- | --- |
| **1. Foundation** | Data infrastructure + biomarker validation | A reliable, multi-modal measure of biological age |
| **2. Prediction** | Perturbation models + causal inference | Correctly predicts intervention effects on held-out systems |
| **3. Discovery** | Hypothesis generation + small-scale validation | Novel targets/compounds validated in cells |
| **4. Automation** | Closed-loop self-driving lab | Thousands of experiments/quarter, iterative improvement |
| **5. Translation** | Animal models → human trials | Healthspan extension, not just lifespan in mice |
Practical requirements: **interdisciplinary teams** (geroscience, ML, robotics, clinical medicine, biostatistics, bioethics), **substantial sustained compute and funding**, and **unusual data-sharing agreements** — aging data is fragmented across institutions and is the main rate-limiter.
- 5. Honest caveats
- **No current system cures aging.** State of the art extends lifespan in mice and worms; translating that to humans is unsolved. Anyone claiming otherwise is selling something.
- **The bottleneck is causal data, not algorithms.** A better model trained on the same correlational data gets you surprisingly little.
- **Validation is irreducibly slow.** Human lifespan trials take decades; surrogate biomarkers are the workaround, and their validity is itself contested.
- **"Exceeding human knowledge" is not "exceeding human judgment."** The system will generate confident, wrong mechanisms. Redundant, adversarial validation and human scientific judgment stay in the loop permanently.
---
- Conclusion
The design is a **closed-loop scientific system**, not a chatbot: a foundation-model stack over multi-omic and perturbation data, a causal-reasoning layer that separates aging *drivers* from *passengers*, an autonomous experimentation layer that compresses the hypothesis–test cycle, and a measurement/safety layer built on validated biomarkers of biological age. Build it in stages — **measure first, predict second, discover third, automate fourth, translate last.** The way an AI exceeds human knowledge is by searching experimental space millions of times faster than we can and integrating across biological scales we can't individually hold — which is why the wet lab, not the model, is where the cure actually comes from.